SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike stock is experiencing intense volatility and a sharp multi-year price decline following a weak outlook and concerns over declining demand in China. While the community remains deeply divided, with some investors betting on a generational value play due to the brand's iconic status and dividend, others are aggressively shorting the stock, citing poor leadership, brand dilution, and concerns that the company's growth model is fundamentally broken.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is seeing heightened volatility and intense social media debate as investors react to the company's pause in Bitcoin accumulation and ongoing concerns regarding stock dilution. The community remains deeply polarized, with bulls pointing to the company's long-term Bitcoin treasury strategy while vocal critics argue that the reliance on equity offerings to fund operations creates an unsustainable path for shareholders.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending following a surprise leadership overhaul that replaced CEO Peter Greenleaf with board chair Kevin Tang, a move widely interpreted by the community as a strategic catalyst for an accelerated company sale. Shareholders are actively debating whether Tangs decision to forgo compensation and his recent heavy accumulation of shares signals an imminent buyout or a shift toward aggressive value maximization.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

Restoration Hardware is experiencing significant volatility following a mixed quarterly report where revenue beat analyst estimates while earnings fell short of expectations. The community remains deeply divided, with bulls pointing to the company's long-term luxury ecosystem strategy and potential tariff relief as major catalysts, while bears warn of ongoing debt pressures, weakening housing trends, and a business model struggling to sustain high-end demand.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets, Data Centers, and Treasury and Corporate. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The Treasury and Corporate segment includes the company’s proprietary trading and mining activities, as well as the company’s principal investments and related gains and losses. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Tema ETF Trust - Tema Space Innovators ETF

The Tema Space Innovators ETF (NASA) is gaining significant community attention as a new, pure-play vehicle offering direct exposure to SpaceX and other space exploration companies ahead of anticipated industry milestones. Investors are actively debating the fund's early AUM and liquidity, drawing frequent comparisons to other space-themed ETFs and speculating on potential price momentum as interest in commercial space activity intensifies.

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

ORIC Pharmaceuticals Inc

ORIC Pharmaceuticals is trending following a significant clinical update regarding its Phase 1b trial of rinzimetostat in combination with darolutamide for prostate cancer. While the stock faced an intraday slump due to concerns over safety signals at higher doses, community discussion remains heavily divided between those viewing the selloff as an exaggerated overreaction with upside potential and those concerned about the broader implications for EZH2-targeting drug classes.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is experiencing high volatility as investors track its history as a parabolic runner, leading to intense debate over whether it is primed for another short squeeze or remains a high-risk pump-and-dump scheme. Community discussion is heavily focused on the stock's low float, rising cost-to-borrow fees, and speculation regarding potential retail-driven "meme" momentum compared to its past price spikes.

Wingstop, Inc. is a franchisor and chicken wings-focused restaurant. The firm is engaged in the flavor business offering cooked-to-order, hand-sauced, and tossed classic and boneless wings, tenders and chicken sandwiches in flavors, with signature sides, such as its seasoned fries and house made ranch and bleu cheese dips. The company was founded in 1994 and is headquartered in Dallas, TX.

Wingstop Inc

Wingstop is experiencing intense volatility and downward pressure as investors debate whether the stock is an oversold growth opportunity or a bubble facing a severe consumer discretionary correction. While bullish participants point to the company's aggressive store expansion, share buybacks, and international potential as reasons to buy the dip, bears are aggressively shorting the stock, citing concerns over same-store sales declines, high valuations, and broader fears of consumer exhaustion impacting the restaurant sector.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is currently experiencing intense market volatility as investors weigh the recent FDA approval of YARTEMLEA and a significant multi-billion dollar partnership with Novo Nordisk against persistent short-selling pressure. The community is actively discussing the stock's apparent undervaluation relative to its clinical milestones and best-in-class product potential, while eagerly awaiting definitive revenue data from upcoming quarterly earnings reports to justify a potential long-term price recovery.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


agentnowager

agentno wager